about
Diabetes and cardiovascular disease: let's push forward with translational researchEpigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective.Insulin resistance, diabetes, and cardiovascular risk.Molecular pathways of arterial aging.Targeting chromatin remodeling to prevent cardiovascular disease in diabetes.Ageing, metabolism and cardiovascular disease.Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting.Mechanisms-based therapeutic strategies in type 2 diabetes.2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps.Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.Shooting vascular oxidative stress: new hopes for stroke patients?Epigenetics and cardiovascular regenerative medicine in the elderly.Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.Empagliflozin across the stages of diabetic heart disease.Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways.Residual SYNTAX score following coronary artery bypass grafting.Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury.Image integration guided ablation of left outflow tract ventricular tachycardia: Is coronary angiography still necessary?The epigenetic landscape in the cardiovascular complications of diabetesEpigenetic processing in cardiometabolic diseasePost-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental strokeThe elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease riskAtrial fibrillation in the cardiometabolic patientHyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66 ShcCorrigendum to 'Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury' [Int. J. Cardiol. 260 (2018) 148-155]Epigenetic Control of Mitochondrial Function in the VasculatureEndothelial SIRT6 blunts stroke size and neurological deficit by preserving blood-brain barrier integrity: a translational studyPCSK9 in diabetes: sweet, bitter or sour?Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathyExercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC)Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue FactorAn overview of the molecular mechanisms underlying development and progression of bicuspid aortic valve diseaseCardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3MicroRNA-122 in heart failure with reduced ejection fraction: Epiphenomenon or causal?Predictors of Successful Ultrasound Guided Femoral Vein Cannulation in Electrophysiological ProceduresGLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trialsThromboembolic Events Following Atrial Fibrillation Cardioversion and Ablation: What's the Culprit?Epigenetic modulation of tenascin C in the heart: implications on myocardial ischemia, hypertrophy and metabolismSirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1Sex-related differences in the aging brain: Time for precision medicine?
P50
Q36174447-FBC5AF3A-26C3-4982-8DAA-75ACDFE87004Q38146195-5EA6E531-22C6-40C4-A05A-9D3D084A73AEQ38208221-0C8C2547-58D5-49C4-947E-75E930C0EAE7Q38252544-A97037FA-C87D-41E4-BBE3-1DE1843F6A56Q38414274-4CA87EDC-2C9F-4964-8F8B-6A5FACC922AEQ38590519-88807442-36E2-4F1E-BF6C-F49B127B56C7Q40174276-602392C9-270D-4A20-86EA-7B620E132C23Q43214637-94108508-CB17-4165-93A8-F608D510796FQ44633782-BE30840A-7BF3-4E41-A727-FF50901EE7A0Q46273298-27DBC26B-B0CB-4FB9-992B-346F00B2C230Q48190123-8243FFBC-18B9-4E69-AFE4-99E79A18A891Q49497454-214823F5-0668-4312-A11B-B04E7CBC6A0BQ50082577-2BD204BD-89D3-4A91-B875-088FCA9E3306Q50094178-71DE2BCF-079E-4027-8E5E-BFA31BEBD3F5Q50892176-84751690-968D-4B09-BB16-A75B152BDBD7Q50994129-87C96B50-0B92-4755-86CD-AEF6C1AB8425Q52603987-1E945366-A6CF-452D-AAED-946BF7BA9BF6Q55221506-78F548E6-A6C3-4C77-866B-9A7185C3B4E1Q57022159-1C2477C2-5E9F-4117-80A9-F43F15DC3E28Q57069024-BD9D010C-97BC-480F-A04B-6A5B559006B3Q57182656-3282DEC6-77D7-45F8-9AC6-90AE2AD785AAQ57314982-32CA1E46-1EB3-4DCB-82CF-E4036FB1C0A5Q58105499-B355321B-537D-4B7D-AE76-886813EFB0A3Q61865820-41154370-34B4-472A-9899-CE428FD2B463Q90211247-5C2F7420-EF84-428A-BCD4-1EC370EC0740Q90484556-0D8F52FD-A038-4387-9CE7-190ADB1A702FQ90650049-326BEBF6-7A4C-4F92-B5A9-41472E0F2C51Q90806485-4BB15C76-E5E1-4D42-8513-9729449296B3Q90980997-AB96B8DF-CA62-4119-BC25-A0263B638B59Q91041609-EC39B41D-DE67-4172-AD8D-9A920DC4AC12Q91514025-0AB9ADAA-EB06-4C3E-8822-0DECBD99CB04Q92134996-A1C3C803-9445-4253-9129-404552D3FF6CQ92138255-06D4318A-54BE-4D40-8DA4-627B54D81CBCQ92285988-CD28F84A-C16F-4591-AA7D-DDFBBD9B76C7Q92358981-D1D03538-8D71-4218-A0D4-F615A329F7F0Q92706749-041F99E8-62B3-4665-A09F-7C94D6D17860Q92753280-74BC2E3E-8748-4E6F-8E75-855A7E02D344Q92873827-3C40B271-47FB-4EF2-93D4-BE65F20ABFBDQ92876900-C4F0E5E3-F6E4-4EC5-95A0-5440586D1C62Q92991874-FDB96D7A-929D-4E7B-81A7-CC304A91F877
P50
description
researcher
@en
wetenschapper
@nl
name
Francesco Paneni
@en
Francesco Paneni
@nl
type
label
Francesco Paneni
@en
Francesco Paneni
@nl
prefLabel
Francesco Paneni
@en
Francesco Paneni
@nl
P108
P31
P496
0000-0001-6483-7844